Zum Hauptinhalt springen
xMedica

NCT06056830ClinicalTrials.gov

Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy: A Prospective, Single-arm, Multi-center, Blinded-review, Phase 3 Diagnostic Performance Study

RekrutiertNimmt laut Registereintrag derzeit Teilnehmende auf.
Diese Studie kontaktieren

Kurz gefasst

The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.

Phase 3383 Teilnehmende gesucht34 Studienzentren3 Länder

Kategorien

In 1 Register registriert

Eine Studie kann in mehreren Registern registriert sein. Wir zeigen sie einmal und verlinken jeden Eintrag, den wir haben.

Die Studieninformationen werden so angezeigt, wie sie vom Register veröffentlicht wurden, in ihrer Originalsprache.

Interesse an dieser Studie?

Anmelden oder ein Konto erstellen um Ihr Interesse zu bekunden und diese Studie zu verfolgen.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2023-09-28; recorded start 2023-12-21
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Not stated: Participants are not randomly assignedAllocation is recorded as non-randomised
  • Not stated: A comparison group is not stated in the registry recordThe record describes a single study arm
  • Not stated: Open label (no blinding)Masking is recorded as none (open label)
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 4 other studies in this databaseCounted from the lead sponsor named in the record (Clarity Pharmaceuticals Ltd)
  • Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
  • The record lists 2 conditions.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourEXPLORATORY

An exploratory-stage design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation0/20

    Allocation not stated in the record

  • Blinding0/20

    Open-label

  • Control arm0/15

    No comparator arm stated in the record

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 31 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study, international in scope: 383 participants (target), run at 34 sites, across 3 countries.

How this score is built
  • Enrolment25/40

    383 participants (target)

  • Site count18/25

    31 sites

  • Country count7/15

    3 countries

  • Planned duration8/10

    Planned over about 33 months

  • Sponsor scale2/10

    Clarity Pharmaceuticals Ltd has led 5 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Zusammenfassung

The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.

Erkrankungen

  • Prostate Cancer
  • Prostatic Neoplasms

Eignung

Eignung
GeschlechtMännlich
Alter18 YearsKein Höchstalter
Gesunde FreiwilligeNein

Eignung im Wortlaut des Registers

Inclusion Criteria: * At least 18 years of age. * Signed informed consent. * Untreated, histologically confirmed adenocarcinoma of the prostate. * High-risk or greater PC defined by National Comprehensive Cancer Network Guidelines Version 1.202327 (clinical stage ≥T3a, or Grade Group ≥4, or PSA \>20 ng/mL). * Patients electing to undergo RP with PLND. Exclusion Criteria: * Administration of any high energy (\>300 KeV) gamma-emitting radioisotope within 5 physical half-lives prior to Day 1. * Known or expected hypersensitivity to 64Cu-SAR-bisPSMA or any of its components. * Patients with known predominant small cell or neuroendocrine PC.

Eignung in einfachen Aussagen

Die Kriterien dieses Eintrags wurden noch nicht in einzelne Aussagen aufgeschlüsselt. Der Registertext oben ist vollständig und ist die maßgebliche Fassung.

Studiendesign

Studiendesign
StudientypInterventionell
PhasePhase 3
ZuteilungNicht zutreffend
InterventionsmodellSINGLE_GROUP
Primäres ZielDIAGNOSTIC
VerblindungNONE (0)
Teilnahme383 Teilnehmende gesucht

Sponsor und Mitwirkende

  • Clarity Pharmaceuticals Ltd Sponsor

Studienarme und Interventionen

  • 64Cu-SAR-bisPSMAEXPERIMENTAL

    200MBq 64Cu-SAR-bisPSMA.

Interventionen

  • Arzneimittel 64Cu-SAR-bisPSMA

    All Patients will receive a single administration, a bolus injection of 200MBq 64Cu-SAR-bisPSMA.

Endpunkte

  1. Primärer Endpunkt

    Diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases

    Independent primary endpoints for Day 1 and Day 2 PET: Co-primary endpoint of sensitivity and specificity of 64Cu-SAR-bisPSMA PET to detect Prostate Cancer within the pelvic lymph nodes compared to the Standard of Truth.

    Zeitrahmen Up to 16 weeks

  2. Sekundärer Endpunkt

    Safety and tolerability of 64Cu-SAR-bisPSMA

    Incidence and severity of treatment-emergent AEs and SAEs following administration of 64Cu-SAR-bisPSMA

    Zeitrahmen Up to 16 weeks

  3. Sekundärer Endpunkt

    Consistency of 64Cu-SAR-bisPSMA PET/CT interpretations for the three central readers

    Inter-reader reliability of agreement estimated with a multiple-reader kappa statistic

    Zeitrahmen Up to 16 weeks

  4. Sekundärer Endpunkt

    PPV and NPV of 64Cu-SAR-bisPSMA PET to detect PC within the pelvic LNs

    PPV and NPV of 64Cu-SAR-bisPSMA PET to detect PC within the pelvic LNs compared to the Standard of Truth

    Zeitrahmen Up to 16 weeks

  5. Sekundärer Endpunkt

    Ability of 64Cu-SAR-bisPSMA PET to detect Prostate Cancer

    Sensitivity of 64Cu-SAR-bisPSMA PET to detect PC within the prostate gland compared to the Standard of Truth

    Zeitrahmen Up to 16 weeks

  6. Sekundärer Endpunkt

    Diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases without subregion matching

    Sensitivity and specificity of 64Cu-SAR-bisPSMA PET to detect PC within the pelvic LNs compared to the Standard of Truth, without the requirement of subregion (Left or Right) matching between 64Cu-SAR-bisPSMA PET and Standard of Truth

    Zeitrahmen Up to 16 weeks

Daten

Daten
Startdatum21. Dezember 2023 (tatsächlich)
Primärer Abschluss1. September 2026 (geschätzt)
Abschluss1. September 2026 (geschätzt)
Erstveröffentlichung28. September 2023 (tatsächlich)
Zuletzt aktualisiert11. September 2026
Ergebnisse veröffentlichtIm Registereintrag nicht angegeben
Status zuletzt bestätigtSeptember 2026

Tatsächlich bedeutet, dass das Ereignis eingetreten ist. Geschätzt bedeutet, dass der Sponsor es erwartet. Die beiden bedeuten Unterschiedliches.

Standorte

34 Studienzentren rekrutieren

Australia

Australia
EinrichtungStadtBundesland oder RegionStatus
Fiona Stanley HospitalMurdochWestern AustraliaRekrutiert
RAMSAY HEALTH CARE AUSTRALIA PTY LIMITED (ABN 36 003 184 889) trading as Hollywood Private HospitalNedlandsWestern AustraliaRekrutiert
St. Vincent's SydneySydneyNew South WalesRekrutiert
Princess Alexandra HospitalWoolloongabbaQueenslandRekrutiert

Puerto Rico

Puerto Rico
EinrichtungStadtBundesland oder RegionStatus
Pan American Center for Oncology Trials, LLC - CiudadelaSan JuanRekrutiert

United States

United States
EinrichtungStadtBundesland oder RegionStatus
Albany Medical College, Department of UrologyAlbanyNew YorkRekrutiert
Urology Austin, PLLC - Research DepartmentAustinTexasRekrutiert
University of Alabama Birmingham HospitalBirminghamAlabamaRekrutiert
University of Texas Southwestern Medical CenterDallasTexasRekrutiert
Urology Clinics of North TexasDallasTexasRekrutiert
Duke University Medical CenterDurhamNorth CarolinaRekrutiert
NorthShore University Health System, Glenbrook HospitalGlenviewIllinoisRekrutiert
BAMF HealthGrand RapidsMichiganRekrutiert
Corewell HealthGrand RapidsMichiganRekrutiert
Indiana University School of MedicineIndianapolisIndianaRekrutiert
Mayo Clinic- JacksonvilleJacksonvilleFloridaRekrutiert
Arkansas Urology Research Center, LLCLittle RockArkansasRekrutiert
Greater Los Angeles VA Medical CenterLos AngelesCaliforniaRekrutiert
Urology Group of Southern CaliforniaLos AngelesCaliforniaRekrutiert
University of WisconsinMadisonWisconsinRekrutiert
Biogenix Molecular, LLCMiamiFloridaRekrutiert
Intermountain HealthMurrayUtahRekrutiert
Carolina Urologic Research CenterMyrtle BeachSouth CarolinaRekrutiert
Urology Associates of NashvilleNashvilleTennesseeRekrutiert
Mount Sinai Doctors Urology Faculty PracticeNew YorkNew YorkRekrutiert
XCancer Omaha LLCOmahaNebraskaRekrutiert
UC Irvine HealthOrangeCaliforniaRekrutiert
Mayo Clinic- PhoenixPhoenixArizonaRekrutiert
Mayo Clinic- RochesterRochesterMinnesotaRekrutiert
The Urology PlaceSan AntonioTexasRekrutiert
Oregon UrologySpringfieldOregonRekrutiert
Stanford University Medical CenterStanfordCaliforniaRekrutiert
Urologic SpecialistsTulsaOklahomaRekrutiert
Wichita Urology GroupWichitaKansasRekrutiert

Studiendokumente

In diesem Registereintrag sind keine Dokumente verlinkt.

Änderungen im Zeitverlauf

  1. 11. September 2026

    Studienzentrum hinzugefügt

    3 sites added (34 total)

    3134